Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2009-05-01
2010-10-19
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C435S069100, C435S252300, C435S471000, C530S350000
Reexamination Certificate
active
07815917
ABSTRACT:
The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.
REFERENCES:
patent: 5707826 (1998-01-01), Wagner et al.
patent: 5962637 (1999-10-01), Shone et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6022950 (2000-02-01), Murphy
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6221355 (2001-04-01), Dowdy
patent: 6337386 (2002-01-01), Shone et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6426075 (2002-07-01), Fitzgerald et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6461834 (2002-10-01), Dormady et al.
patent: 6504006 (2003-01-01), Shine et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 6831059 (2004-12-01), Donovan
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7183066 (2007-02-01), Fernandez-Salas et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7208285 (2007-04-01), Steward et al.
patent: 7273722 (2007-09-01), Lin et al.
patent: 7419676 (2008-09-01), Dolly et al.
patent: 7422877 (2008-09-01), Dolly et al.
patent: 7498148 (2009-03-01), Wagner et al.
patent: 7556817 (2009-07-01), Steward et al.
patent: 2002/0137886 (2002-09-01), Lin et al.
patent: 2002/0168727 (2002-11-01), Smith et al.
patent: 2003/0143650 (2003-07-01), Steward et al.
patent: 2003/0143651 (2003-07-01), Steward et al.
patent: 2004/0018589 (2004-01-01), Zhong
patent: 2004/0072270 (2004-04-01), Fernandez-Salas et al.
patent: 2004/0219619 (2004-11-01), Fernandez-Salas et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2006/0110410 (2006-05-01), Shone et al.
patent: 2006/0134722 (2006-06-01), Chapman et al.
patent: 2006/0154314 (2006-07-01), Steward et al.
patent: 2006/0204524 (2006-09-01), Ichtchenko et al.
patent: 2006/0211619 (2006-09-01), Steward et al.
patent: 2007/0218001 (2007-09-01), Delagrave
patent: 2007/0248626 (2007-10-01), Shone et al.
patent: 2008/0032930 (2008-02-01), Steward et al.
patent: 2008/0081355 (2008-04-01), Dolly et al.
patent: 2008/0161226 (2008-07-01), Steward et al.
patent: 2008/0221012 (2008-09-01), Steward et al.
patent: 2008/0305510 (2008-12-01), Williams et al.
patent: 2008/0311622 (2008-12-01), Dolly et al.
patent: 2009/0004224 (2009-01-01), Steward et al.
patent: 2009/0005313 (2009-01-01), Steward et al.
patent: 2009/0018081 (2009-01-01), Steward et al.
patent: 2009/0030182 (2009-01-01), Dolly et al.
patent: 2009/0030188 (2009-01-01), Dolly et al.
patent: 2009/0042270 (2009-02-01), Dolly et al.
patent: 2009/0069238 (2009-03-01), Steward et al.
patent: 2009/0081730 (2009-03-01), Dolly et al.
patent: 2009/0087458 (2009-04-01), Dolly et al.
patent: 98/07864 (1998-02-01), None
patent: 00/61768 (2000-10-01), None
patent: WO 00/61192 (2000-10-01), None
patent: 01/14570 (2001-03-01), None
patent: 02/44199 (2002-06-01), None
patent: 03/020948 (2003-03-01), None
patent: 2004/024909 (2004-03-01), None
patent: 2005/023309 (2005-03-01), None
patent: 2006/026780 (2006-03-01), None
patent: 2006/059093 (2006-06-01), None
patent: 2006/059105 (2006-06-01), None
Wictome, Matthew et al, FEBS Letters, vol. 386, pp. 133-136, 1996, Substrate residues N-terminal to the cleavage site of botulinum type B neurotoxin play a role in determining the specificity of its endopeptidase activity.
Evans et al, Toxicon, vol. 46, pp. 446-453, 2005 Analysis of the substrate recognition domain determinants of Botulinum type B toxin using Phage Display.
Ahmed, S.A., et al., Enzymatic Autocatalysis of Botulinum A Neurotoxin Light Chain, 20(3) J. Protein Chem. 221-231 (2001).
Breidenbach et al, “Substrate recognition strategy for botulinum neurotoxin serotype A”, Nature, vol. 432, No. 7019, pp. 925-929, Dec. 2004.
Breidenbach et al, “New insights into clostridial neurotoxin-SNARE interactions”, Trends in Molecular Medicine, vol. 11, No. 8, pp. 377-381, Aug. 2005.
Chaddock et al, “Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A”, Protein Expression and Purification, vol. 25, No. 2, pp. 219-228, Jul. 2002.
Fasshauer, Dirk et al, PNAS, USA, vol. 95, pp. 15781-15786, Dec. 1998, Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q and R-SNAREs.
Johnson, “Clostridial Toxins as Therapeutic Agents: Benefits of Nature's Most Toxic Proteins”, Annual Review of Microbiology, vol. 53, pp. 551-575, 1999.
Li, Y., et al., Recombinant Forms of Tetanus Toxin Engineered for Examining and Exploiting Neuronal Trafficking Pathways, 276(33) J. Biol. Chem. 31394-31401 (2001).
Rawlings et al, “MEROPS: the protease database”, Nucleic Acids Research, vol. 30, No. 1, 343-346, 2002.
Rossi, Valeria et al, Biology of the Cell, vol. 96, pp. 251-256, 2004, VAMP subfamilies identified by specific R-SNARE motifs.
Sutton, J.M., et al., Preparation of Specifically Activatable Endopeptidase Derivatives of Clostridium botulinum Toxins Type A, B, and C and Their Applications, 40(2005) Protein Expr. Purif. 31-41 (2005).
Swiss Prot Accession No. P10845.
Turton et al, “Botulinum and tetanus neurotoxins: structure, function and therapeutic utility”, vol. 27, No. 11, pp. 552-558, Nov. 2002.
Washbourne, Philip et al, FEBS letters, vol. 418, pp. 1-5, 1997, Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis.
Oka Melvin S.
Steward Lance E.
Allergan Inc.
Allergan, Inc.
German Joel B.
Mondesi Robert B
Portner Ginny
LandOfFree
Botulinum neurotoxin serotype B activatable Botulinum... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum neurotoxin serotype B activatable Botulinum..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum neurotoxin serotype B activatable Botulinum... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239856